Alpine Immune Sciences, Inc. (ALPN) Receives Average Recommendation of “Hold” from Brokerages
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) have been given an average recommendation of “Hold” by the five research firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $9.75.
Several equities analysts recently commented on the stock. ValuEngine lowered shares of Alpine Immune Sciences from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 11th. Zacks Investment Research lowered shares of Alpine Immune Sciences from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 26th.
An institutional investor recently bought a new position in Alpine Immune Sciences stock. Sowell Financial Services LLC acquired a new position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,714 shares of the biotechnology company’s stock, valued at approximately $162,000. Sowell Financial Services LLC owned approximately 0.40% of Alpine Immune Sciences as of its most recent SEC filing.
Shares of Alpine Immune Sciences (NASDAQ ALPN) traded up $0.06 during mid-day trading on Monday, reaching $11.38. 16,297 shares of the company traded hands, compared to its average volume of 55,020. Alpine Immune Sciences has a 1 year low of $7.20 and a 1 year high of $14.52. The company has a quick ratio of 32.38, a current ratio of 32.38 and a debt-to-equity ratio of 0.05.
Alpine Immune Sciences Company Profile
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Alpine Immune Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.